The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients

Table 2 Participant quality of life, disability scores and serology

	HC	ME/CFS	P-value
SF-36 (%)
Physical functioning	96.33 ± 2.89	44.00 ± 7.24	< 0.001
Physical role	93.33 ± 2.89	28.33 ± 6.87	< 0.001
Pain	89.33 ± 3.022	42.833 ± 6.70	< 0.001
General health	79.43 ± 3.48	34.71 ± 4.64	< 0.001
Social functioning	94.16 ± 2.95	34.17 ± 6.03	< 0.001
Emotional role	93.33 ± 3.02	70.00 ± 6.44	0.007
Emotional wellbeing	74.07 ± 4.48	43.82 ± 3.92	< 0.001
WHO DAS (%)
Communication & understanding	7.19 ± 1.96	40.81 ± 4.49	< 0.001
Mobility	2.67 ± 0.83	40.67 ± 7.44	< 0.001
Self-care	0 ± 0	20.41 ± 5.37	0.004
Interpersonal relationships	7.92 ± 2.69	32.91 ± 4.97	< 0.001
Life activities	6.67 ± 2.23	56.25 ± 8.09	< 0.001
Participation in society	3.12 ± 1.55	50.62 ± 5.86	< 0.001
Full blood count
White cell count (× 10⁹/L)	5.40 ± 0.32	6.07 ± 0.48	0.262
Lymphocytes (× 10⁹/L)	1.76 ± 0.15	1.88 ± 0.11	0.517
Neutrophils (× 10⁹/L)	3.07 ± 0.26	3.51 ± 0.38	0.345
Monocytes (× 10⁹/L)	0.40 ± 0.03	0.43 ± 0.04	0.598
Eosinophils (× 10⁹/L)	0.12 ± 0.02	0.18 ± 0.02	0.033
Basophils (× 10⁹/L)	0.04 ± 0.01	0.04 ± 0.004	0.631
Platelets (× 10⁹/L)	239.67 ± 14.59	254.20 ± 11.10	0.435
Red Cell Count (× 10¹²/L)	4.82 ± 0.13	4.67 ± 0.10	0.356
Haematocrit	0.43 ± 0.01	0.42 ± 0.01	0.806
Haemoglobin (g/L)	143.07 ± 4.10	141.0 ± 2.76	0.680

Values in bold indicate statistical significance
HC healthy controls, ME Myalgic encephalomyelitis, CFS chronic fatigue syndrome, SF-36 36-item short form survey, WHO world health organization, DAS disability assessment schedule

ISSN: 1479-5876